# Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis

> **NCT06975150** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CuromeBiosciences** · enrollment: 105 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **DRUG:** HK-660S 100mg
- **DRUG:** HK-660S 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06975150
- **Lead sponsor:** CuromeBiosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975150, "Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06975150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*